NASDAQ:TERN Terns Pharmaceuticals Q3 2024 Earnings Report ProfileEarnings HistoryForecast Terns Pharmaceuticals EPS ResultsActual EPS-$0.28Consensus EPS -$0.33Beat/MissBeat by +$0.05One Year Ago EPSN/ATerns Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATerns Pharmaceuticals Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call DateTuesday, November 12, 2024Conference Call Time9:30AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly Report(10-Q) Terns Pharmaceuticals Earnings HeadlinesMerck cuts 2026 profit forecast on Terns acquisition chargesAugust 4, 2026 | finance.yahoo.comHow The Merck (MRK) Investment Story Is Shifting With Terns Deal And Oncology UpdatesMay 18, 2026 | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 22 at 1:00 AM | Porter & Company (Ad)Merck Completes Acquisition of Terns Pharmaceuticals, Inc.May 5, 2026 | businesswire.comMerck still sees ‘compelling’ outlook for Terns leukemia drugApril 30, 2026 | finance.yahoo.comOppenheimer downgrades Terns Pharmaceuticals (TERN)April 28, 2026 | msn.comSee More Terns Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Terns Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Terns Pharmaceuticals and other key companies, straight to your email. Email Address About Terns PharmaceuticalsTerns Pharmaceuticals (NASDAQ:TERN) is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies. The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation. These include inhibitors of key pathways implicated in nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), as well as programs directed at hepatocellular carcinoma. Each candidate is being investigated for its ability to modulate disease drivers such as bile acid metabolism, immune cell activation and cell‐signaling cascades involved in fibrosis. Terns leverages state‐of‐the‐art medicinal chemistry and translational biology platforms to optimize both efficacy and safety profiles across its portfolio. Headquartered in San Diego, California, Terns Pharmaceuticals operates in a hub known for innovation in hepatology and liver disease research. The company’s management and scientific leadership bring extensive experience from established biotech and pharmaceutical organizations, with deep expertise in clinical development, regulatory strategy and commercialization planning. By combining this leadership team’s industry knowledge with strategic partnerships and academic collaborations, Terns is positioned to advance its therapeutic candidates toward regulatory milestones and, ultimately, broaden treatment options for patients suffering from severe liver diseases.View Terns Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep Winning Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
